Integra LifeSciences Sees Q4 Revenue At Higher End Of Prior Guidance

(RTTNews) - Integra LifeSciences Holdings Corp. (IART) said it expects reported revenue for the fourth quarter of 2018 to be at the higher end of its previous guidance range of $378 million to $383 million. Organic revenue growth in the fourth quarter 2018 is expected to be slightly above 4%. Analysts polled by Thomson Reuters expects the company to report earnings revenues of $380.76 million for the fouth-quarter. Analysts' estimates typically exclude special items.

Integra LifeSciences also said it has signed a license and development agreement with Consortium of Focused Orthopedists, LLC, for a short stem and stemless shoulder system.